INTRODUCTION: Pulsed electric field (PEF) has emerged as a promising energy source for catheter ablation of atrial fibrillation (AF). However, data regarding the in-vivo effect of PEF energy on erythrocytes during AF ablation procedures are scarce. This study aimed to quantify the impact of PEF energy on erythrocyte damage during AF ablation by assessing specific hemolytic biomarkers. METHODS: A total of 60 patients (age: 68 years, males: 72%, serum creatinine: 91 µmol/L) with AF underwent catheter ablation of AF using PEF energy delivered by a multipolar pentaspline Farawave catheter (Farapulse, Boston Scientific, Inc.). Ablation beyond pulmonary vein isolation was performed at the operator's discretion. Peripheral venous blood was sampled for assessing the plasma levels of free hemoglobin (fHb), direct (conjugated) bilirubin, lactate dehydrogenase (LDH), and creatinine before, immediately after the ablation, and on the next day. RESULTS: Following the PEF ablation with duration of [median (interquartile range)] 75 (58, 95) min, with 74 (52, 92) applications and PVI only in 27% of patients, fHb, LDH, and direct bilirubin significantly increased, from 40 (18, 65) to 493 (327, 848) mg/L, from 3.1 (2.6, 3.6) to 6.8 (5.0, 7.9) µkat/L, and from 12 (9, 17) to 28 (16, 44) µmol/L, respectively (all p < .0001). A strong linear correlation was found between the peak fHb and the number of PEF applications (R = 0.81, p < .001). The major hemolysis (defined as fHb >500 mg/L) was predicted by the number of PEF applications with the corresponding area under the receiver operating characteristic curve of 0.934. The optimum cut-off value of >74 PEF applications predicted the major hemolysis with 89% sensitivity and 87% specificity. CONCLUSION: Catheter ablation of AF using PEF energy delivered from a pentaspline catheter is associated with significant intravascular hemolysis. More than 74 PEF applications frequently resulted in major hemolysis. However, the critical amount of PEF energy that may cause kidney injury in susceptible patients remains to be investigated.
- Klíčová slova
- acute kidney injury, atrial fibrillation, hemolysis, pulsed field ablation,
- MeSH
- bilirubin krev MeSH
- biologické markery * krev MeSH
- časové faktory MeSH
- design vybavení MeSH
- erytrocyty MeSH
- fibrilace síní * chirurgie diagnóza patofyziologie krev MeSH
- hemoglobiny metabolismus MeSH
- hemolýza * MeSH
- katetrizační ablace * škodlivé účinky přístrojové vybavení MeSH
- kreatinin krev MeSH
- L-laktátdehydrogenasa krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- prediktivní hodnota testů MeSH
- rizikové faktory MeSH
- senioři MeSH
- srdeční katétry MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- bilirubin MeSH
- biologické markery * MeSH
- hemoglobiny MeSH
- kreatinin MeSH
- L-laktátdehydrogenasa MeSH
BACKGROUND: In December 2019, a new coronavirus, SARS-CoV-2, appeared in Wuhan, China. This virus is the cause of the COVID-19 disease. This infection later spread to the whole world. The goal of this article is to present the clinical and laboratory characteristics of patients with COVID-19 treated in the Faculty Hospital Pilsen. METHODS: In this monocentric, retrospective study, clinical and biochemical data of 89 adult patients with COVID-19 was analyzed. These patients were in the care of the Faculty Hospital Pilsen between March 14 and April 7. RESULTS: In this cohort, made up of 89 patients, 63 were treated as outpatients and 26 were hospitalized. 10 patients required intensive care. The most common symptoms among patients were cough and fever. Dyspnea was present in 29 patients. A CT scan showed bilateral pneumonia in 23 of the admitted patients. Fever and bilateral pneumonia were significantly more common in patients ≥ 60 years old (p=0.047, and p=0.001, respectively). Of lab results, the patients in intensive care had significantly higher values of C-reactive protein, procalcitonin, lactate dehydrogenase, interleukin 6, myoglobin and ferritin. CONCLUSION: The most common symptoms of COVID-19 are fever and cough. These two symptoms are simultaneously present in more than half the cases. Approximately 1/10th of patients requires intensive care. Higher values of lactate dehydrogenase, myoglobin and ferritin on patient admission appear to be a strong predictive factor of the patient's status progressing into requiring ICU attention.
- MeSH
- ambulantní péče statistika a číselné údaje MeSH
- artralgie patofyziologie MeSH
- bolesti hlavy patofyziologie MeSH
- C-reaktivní protein metabolismus MeSH
- COVID-19 krev epidemiologie patofyziologie MeSH
- diabetes mellitus epidemiologie MeSH
- dospělí MeSH
- dyspnoe patofyziologie MeSH
- ferritiny krev MeSH
- horečka patofyziologie MeSH
- hospitalizace statistika a číselné údaje MeSH
- hypertenze epidemiologie MeSH
- interleukin-6 krev MeSH
- jednotky intenzivní péče MeSH
- kašel patofyziologie MeSH
- komorbidita MeSH
- L-laktátdehydrogenasa krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- myalgie patofyziologie MeSH
- myoglobin krev MeSH
- obezita epidemiologie MeSH
- počítačová rentgenová tomografie MeSH
- prokalcitonin krev MeSH
- SARS-CoV-2 MeSH
- senioři MeSH
- věkové faktory MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika epidemiologie MeSH
- Názvy látek
- C-reaktivní protein MeSH
- ferritiny MeSH
- interleukin-6 MeSH
- L-laktátdehydrogenasa MeSH
- myoglobin MeSH
- prokalcitonin MeSH
Selenium deficiency is a common nutritional disorder in dairy cattle globally. However, selenium supplementation can lead to selenium toxicity. This study evaluated a novel, low-toxicity selenium supplement, selenitetriglycerides, to determine its efficacy and safety in dairy cows. The study was conducted on 12 Holstein Friesian cows divided in two equal groups (control group without supplementation of selenium and experimental group with supplementation of selenitetriglycerides). Experimental cows (n=6) were orally administered 300 mg/cow/day of selenitetriglycerides for 14 days (days 1-14) and then monitored for a further 14 days (days 15-28). Blood from both groups of cows was sampled for determination of selenium concentrations, activity of aspartate aminotransferase, creatine kinase, lactate dehydrogenase, gamma- -glutamyl transferase, concentrations of triglycerides, cholesterol, non-esterified fatty acids, glucose, total protein, urea, creatinine and hematological parameters. Serum selenium concentrations in the experimental group increased significantly on day 2 (from 64.92±6.89 μg/L to 127.95±13.75 μg/L), peaked on day 7 (266.22±14.21 μg/L) and remained significantly above the initial baseline values (day 1) for 28 days. Serum selenium concentrations in the control group did not change significantly during the 28 day period (65.22 μg/L on 1st day and 64,35 μg/L on 28th day) and were significantly lower than those in the experimental group from day 2 to day 28. The results of clinical examinations, analyses of hematological parameters, and liver and kidney function tests showed that selenitetriglycerides had no adverse effect on the health or on the metabolic or haematological statuses of the cows. These findings indicate that selenitetriglycerides are safe and effective selenium supplements for cattle.
- Klíčová slova
- biochemical parameters, cattle, haematology, selenitetriglycerides, selenium,
- MeSH
- aspartátaminotransferasy krev metabolismus MeSH
- cholesterol krev MeSH
- gama-glutamyltransferasa krev metabolismus MeSH
- játra účinky léků MeSH
- kreatinin krev MeSH
- kreatinkinasa krev metabolismus MeSH
- krevní glukóza MeSH
- krevní proteiny MeSH
- kyseliny mastné neesterifikované krev MeSH
- L-laktátdehydrogenasa krev metabolismus MeSH
- ledviny účinky léků MeSH
- močovina krev MeSH
- potravní doplňky MeSH
- selen krev MeSH
- skot krev metabolismus MeSH
- sloučeniny selenu chemie farmakologie MeSH
- triglyceridy krev chemie farmakologie MeSH
- zvířata MeSH
- Check Tag
- skot krev metabolismus MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- randomizované kontrolované studie veterinární MeSH
- Názvy látek
- aspartátaminotransferasy MeSH
- cholesterol MeSH
- gama-glutamyltransferasa MeSH
- kreatinin MeSH
- kreatinkinasa MeSH
- krevní glukóza MeSH
- krevní proteiny MeSH
- kyseliny mastné neesterifikované MeSH
- L-laktátdehydrogenasa MeSH
- močovina MeSH
- selen MeSH
- sloučeniny selenu MeSH
- triglyceridy MeSH
The purpose of this study was to assess the prognostic value of lactate dehydrogenase (LDH) in patients with metastatic prostate cancer (PC). A systematic review and meta-analysis was performed in March 2019 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Studies were deemed eligible if they compared patients with PC with high versus low LDH to determine the predictive value of LDH for overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS). We performed a formal meta-analysis for both OS and PFS. A total of 59 articles with 14,851 patients were included in the systematic review and 45 studies with 12,224 patients for the qualitative assessment. High LDH was associated with both worse OS (pooled hazard ratio [HR], 2.07; 95% confidence interval [CI], 1.75-2.44) and PFS (pooled HR, 1.08; 95% CI, 1.01-1.16). In subgroup analyses of both patients with castration-resistant prostate cancer (CRPC) and those with hormone-sensitive prostate cancer (HSPC), LDH was associated with OS (pooled HR, 2.02; 95% CI, 1.69-2.42 and pooled HR, 2.25; 95% CI, 1.78-2.84, respectively). In patients with CRPC, LDH was associated with OS in those treated with docetaxel systemic chemotherapy and androgen receptor-axis-targeting agents (pooled HR, 2.03; 95% CI, 1.37-3.00 and pooled HR, 1.79; 95% CI, 1.25-2.57, respectively). Elevated serum levels of LDH were associated with an increased risk of mortality and progression in patients with metastatic PC. LDH was independently associated with OS in both patients with CRPC and HSPC. LDH could be integrated into prognostic tools that help guide treatment strategy, thereby facilitating the shared decision-making process.
- Klíčová slova
- Castration-resistant prostate cancer (CRPC), Hormone-sensitive prostate cancer (HSPC), Lactate dehydrogenase (LDH), Meta-analysis, Metastatic prostate cancer,
- MeSH
- analýza přežití MeSH
- klinické rozhodování MeSH
- L-laktátdehydrogenasa krev MeSH
- lidé MeSH
- mortalita MeSH
- nádorové biomarkery krev MeSH
- nádory prostaty enzymologie mortalita MeSH
- prognóza MeSH
- progrese nemoci MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- metaanalýza MeSH
- systematický přehled MeSH
- Názvy látek
- L-laktátdehydrogenasa MeSH
- nádorové biomarkery MeSH
BACKGROUND: Risk stratification is crucial to treatment decision-making in neuroblastoma. This study aimed to explore factors present at diagnosis affecting outcome in patients aged ≥18 months with metastatic neuroblastoma and to develop a simple risk score for prognostication. PROCEDURE: Data were derived from the European high-risk neuroblastoma 1 (HR-NBL1)/International Society for Paediatric Oncology European Neuroblastoma (SIOPEN) trial with analysis restricted to patients aged ≥18 months with metastatic disease and treated prior to the introduction of immunotherapy. Primary endpoint was 5-year event-free survival (EFS). Prognostic factors assessed were sex, age, tumour MYCN amplification (MNA) status, serum lactate dehydrogenase (LDH)/ferritin, primary tumour and metastatic sites. Factors significant in univariate analysis were incorporated into a multi-variable model and an additive scoring system developed based on estimated log-cumulative hazard ratios. RESULTS: The cohort included 1053 patients with median follow-up 5.5 years and EFS 27 ± 1%. In univariate analyses, age; serum LDH and ferritin; involvement of bone marrow, bone, liver or lung; and >1 metastatic system/compartment were associated with worse EFS. Tumour MNA was not associated with worse EFS. A multi-variable model and risk score incorporating age (>5 years, 2 points), serum LDH (>1250 U/L, 1 point) and number of metastatic systems (>1, 2 points) were developed. EFS was significantly correlated with risk score: EFS 52 ± 9% for score = 0 versus 6 ± 3% for score = 5 (P < 0.0001). CONCLUSIONS: A simple score can identify an "ultra-high risk" (UHR) cohort (score = 5) comprising 8% of patients with 5-year EFS <10%. These patients appear not to benefit from induction therapy and could potentially be directed earlier to alternative experimental therapies in future trials.
- Klíčová slova
- lactate dehydrogenase, metastatic, neuroblastoma, relapse, risk stratification, ultra-high risk,
- MeSH
- dítě MeSH
- doba přežití bez progrese choroby MeSH
- ferritiny krev MeSH
- Kaplanův-Meierův odhad MeSH
- klinické zkoušky jako téma MeSH
- kojenec MeSH
- L-laktátdehydrogenasa krev MeSH
- lidé MeSH
- nádorové biomarkery analýza MeSH
- neuroblastom mortalita patologie MeSH
- předškolní dítě MeSH
- přežití bez známek nemoci MeSH
- prognóza MeSH
- proporcionální rizikové modely MeSH
- protoonkogen n-myc genetika MeSH
- rizikové faktory MeSH
- sexuální faktory MeSH
- věkové faktory MeSH
- Check Tag
- dítě MeSH
- kojenec MeSH
- lidé MeSH
- mužské pohlaví MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- ferritiny MeSH
- L-laktátdehydrogenasa MeSH
- MYCN protein, human MeSH Prohlížeč
- nádorové biomarkery MeSH
- protoonkogen n-myc MeSH
With the development and subsequent clinical applications of anticancer immuno-and angiomodulatory therapies and expanded knowledge on significance of tumor microenvironment for disease prognosis and treatment outcome, a classical blood analyte, lactate dehydrogenase (LDH), gains in importance as a tumor marker reflecting to some extent immunosupressive and angiogenic tumour milieu. Physical extravascular hemolysis due to complicated or inaccurate blood sampling interferes strongly with quantification of LDH in serum/plasma samples. Upon correlating circulating hemoglobin level with LDH catalytic activities in 99,937 plasma samples we quantified hemolysis interference with LDH plasma levels. An increment of LDH (μkat/l) caused by hemolysis is equal to 0.002 times circulating hemoglobin level (mg/l). Thus, hemolysis interference can be mathematically subtracted from measured LDH using a formula: [LDH (measured) (μkat/l) - 0.002 × circulating hemoglobin (mg/l) ]. In other words, each increment of hemolysis equal to 100mg/l of circulating hemoglobin will result to LDH increase equal to 0.2 μkat/l. As one of the emerging predictors of treatment outcome, a cancer prognostic biomarker and dynamic tumor marker, serum/plasma LDH concentration needs to be interpreted with respect to reported hemolysis level. Also, for these purposes, quantitative determination of serum/plasma levels of free circulating hemoglobin has to be routinely performed.Key words: lactate dehydrogenase - hemolysis - preanalytical error This work was supported by MEYS via NPS I for RECAMO2020 (LO1413). The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.Submitted: 13. 3. 2017Accepted: 26. 3. 2017.
- MeSH
- hemoglobiny analýza MeSH
- hemolýza MeSH
- L-laktátdehydrogenasa krev MeSH
- lidé MeSH
- nádorové biomarkery krev MeSH
- nádory krev MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- hemoglobiny MeSH
- L-laktátdehydrogenasa MeSH
- nádorové biomarkery MeSH
We compared the outcomes of multiple myeloma (MM) patients aged 21-40 and 41-60 years in the novel agent era. This case-control study included 1089 patients between 2000 and 2015. Cases and controls were matched for sex, International Staging System (ISS) stage and institution. There were 173 patients in the younger group and 916 patients in the older group. Younger patients presented with a higher incidence of lytic lesions (82% vs. 72%; P = 0·04) and high-risk cytogenetic abnormalities (83% vs. 68%; P = 0·007), but lower rate of elevated lactate dehydrogenase (21% vs. 44%; P < 0·001). Five- and 10-year overall survival (OS) in younger versus older patients was 83% vs. 67% and 56% vs. 39%, respectively (P < 0·001). Similar results were seen when studying the subset of 780 patients who underwent autologous transplantation. Younger patients with ISS stage 1 had a better OS than older patients (P < 0·001). There was no survival difference between younger and older patients with ISS stage 2 or 3. Younger MM patients, aged 21-40 years, treated in the era of novel agents have a better OS than their counterparts aged 41-60 years, but the survival advantage observed in younger patients was lost in more advanced stages of MM.
- Klíčová slova
- myeloma, outcomes, survival, transplantation, young,
- MeSH
- autologní transplantace MeSH
- chromozomální aberace MeSH
- dospělí MeSH
- L-laktátdehydrogenasa krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- míra přežití MeSH
- mladý dospělý MeSH
- mnohočetný myelom diagnóza mortalita patologie terapie MeSH
- staging nádorů MeSH
- studie případů a kontrol MeSH
- transplantace hematopoetických kmenových buněk metody MeSH
- věkové faktory * MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- Názvy látek
- L-laktátdehydrogenasa MeSH
Recent studies in adult lymphoma patients have indicated a correlation between polymorphisms of Fc gamma-receptors (FcγRs, encoded by the respective FCGR genes) and the response to rituximab treatment. In vitro, cells expressing FcγRIIIa-158V mediate antibody-dependent cellular cytotoxicity (ADCC) more efficiently than cells expressing FcγRIIIa-158F. The impact of the FCGR2A-131HR polymorphism is unclear. In this study, the FCGR polymorphisms FCGR3A-158VF and FCGR2A-131HR were analyzed in pediatric patients with mature aggressive B cell non-Hodgkin lymphoma/leukemia (B-NHL). Pediatric patients received a single dose of rituximab monotherapy. Response was evaluated on day 5 followed by standard chemotherapy for B-NHL. Among 105 evaluable patients, a response to rituximab was observed in 21 % of those homozygous for FcγRIIa-131RR (5/24) compared to 48 % of patients who were HH and HR FcγRIIa-131 allele carriers (18/34 and 21/47, respectively; p = 0.044). Among patients with the FCGR3A-158 polymorphism, those homozygous for the FF genotype had a significantly favorable rituximab response rate of 59 % (22/37) compared to 32 % in patients who were FcγRIIIa-158VV and FcγRIIIa-VF allele carriers (2/9 and 20/59, respectively; p = 0.022). A stringent phase II response evaluation of children and adolescents with B-NHL after one dose of rituximab monotherapy showed a significant association between the rituximab response rate and FCGR polymorphisms. These findings support the hypothesis that FCGR polymorphisms represent patient-specific parameters that influence the response to rituximab.
- Klíčová slova
- Fc gamma-receptor, Lymphoma, Oncology, Response, Rituximab,
- MeSH
- B-buněčný lymfom krev farmakoterapie genetika MeSH
- dítě MeSH
- frekvence genu MeSH
- genotyp MeSH
- indukce remise MeSH
- jednonukleotidový polymorfismus * MeSH
- L-laktátdehydrogenasa krev metabolismus MeSH
- lidé MeSH
- lokální recidiva nádoru MeSH
- mladiství MeSH
- multivariační analýza MeSH
- prognóza MeSH
- protinádorové látky terapeutické užití MeSH
- receptory IgG genetika MeSH
- rituximab terapeutické užití MeSH
- výsledek terapie MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- FCGR2A protein, human MeSH Prohlížeč
- FCGR3A protein, human MeSH Prohlížeč
- L-laktátdehydrogenasa MeSH
- protinádorové látky MeSH
- receptory IgG MeSH
- rituximab MeSH
BACKGROUND: Serum lactate dehydrogenase (LDH) has been reported as a prognostic biomarker in malignant diseases. However, little is known on the dynamics of serum LDH levels during systemic treatment. We focused on the association of changes in serum LDH with outcome of patients with advanced-stage non-small cell lung cancer (NSCLC) treated with erlotinib. PATIENTS AND METHODS: Clinical data of 309 patients were analyzed. Serum samples were collected within one week before initiation and after one month of treatment. RESULTS: The change in serum LDH during the first month of erlotinib treatment was independently associated with disease control rate (p=0.006), progression-free survival (PFS) (p=0.010) and overall survival (OS) (p<0.001). CONCLUSION: LDH is a commonly used serum biomarker, that is cheap and easy to detect. The results of our study suggest that the change in LDH serum level during the first month is a surrogate marker on the efficacy of erlotinib in patients with advanced NSCLC.
- Klíčová slova
- EGFR-TKI, LDH, Lactate dehydrogenase, NSCLC, biomarker, erlotinib, lung cancer, prediction,
- MeSH
- dospělí MeSH
- erlotinib terapeutické užití MeSH
- L-laktátdehydrogenasa krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory plic krev farmakoterapie MeSH
- nemalobuněčný karcinom plic krev farmakoterapie MeSH
- protinádorové látky terapeutické užití MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- erlotinib MeSH
- L-laktátdehydrogenasa MeSH
- protinádorové látky MeSH
Cyanobacteria are producers of potent and environmentally abundant microcystins, representing an emerging global health issue. In the present study, we investigated the impact of cyanobacterial biomass on biochemical indices of common carp (Cyprinus carpio L., average weight of 246 ± 73 g) under laboratory conditions. The fish were fed a diet containing cyanobacterial biomass with microcystins in high concentration (0.4 mg/kg of fish weight and day) for 28 days. Statistical evaluation of the influence of the cyanobacterial biomass in food on the biochemical indices of the juvenile carp showed only minor differences. The activity of aspartate aminotransferase value and the urea concentration were significantly reduced compared to control group. The biochemical parameters of fish blood plasma significantly rose during the experiment in the control group as well as in the experimental group. This state was probably influenced by the environmental conditions and the fish diet. A significant rising value was established in calcium creatinine, total protein, phosphorus, lactate, urea and natrium. The present study demonstrates that the oral exposure of toxic cyanobacterial biomass has a minor influence on the biochemical indices of common carp and that the effect of other factors, e.g., nutrition is more visible.
- MeSH
- alanintransaminasa MeSH
- bakteriální toxiny krev toxicita MeSH
- bilirubin krev MeSH
- chloridy MeSH
- cholesterol krev MeSH
- dieta veterinární MeSH
- draslík krev MeSH
- fyziologie výživy zvířat MeSH
- kapři krev fyziologie MeSH
- krmivo pro zvířata analýza MeSH
- L-laktátdehydrogenasa krev MeSH
- mikrocystiny chemie toxicita MeSH
- mořské toxiny krev toxicita MeSH
- sérový albumin analýza MeSH
- sinice chemie MeSH
- železo krev MeSH
- zvířata MeSH
- Check Tag
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- alanintransaminasa MeSH
- bakteriální toxiny MeSH
- bilirubin MeSH
- chloridy MeSH
- cholesterol MeSH
- draslík MeSH
- L-laktátdehydrogenasa MeSH
- mikrocystiny MeSH
- mořské toxiny MeSH
- sérový albumin MeSH
- železo MeSH
